- Free worldwide shipping, tracked and insured
- Same day dispatch, customs handled
- Certificate of analysis for every batch
- Dual-pathway GH secretagogue research (GHRH + ghrelin receptor)
- Pulsatile growth hormone release studies
- Selective GH signaling with minimal off-target hormonal effects in studies
Overview
What is CJC-1295 + Ipamorelin Blend?
The CJC-1295 + Ipamorelin blend is a research compound pairing a growth hormone-releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R1a) secretagogue, at 5mg of each per 10mg vial. It is used to study combined growth hormone pathway signaling in vitro. Supplied for laboratory research use only.
Blend Composition
- CJC-1295 (No DAC) · GHRH Analog
- 5mg
- Ipamorelin · Ghrelin Agonist
- 5mg
Reference data
CJC-1295 + Ipamorelin Blend specifications
- Composition
- 5mg CJC-1295 (No DAC) + 5mg Ipamorelin
- CJC-1295 class
- Synthetic GHRH(1-29) analogue (modified, No DAC)
- Ipamorelin class
- Synthetic pentapeptide GH secretagogue (GHRP)
- Total amount per vial
- 10mg co-lyophilized blend
- Appearance
- White lyophilized powder
- Solubility
- Soluble in bacteriostatic water
- Purity
- 99.4%
Research applications
Where CJC-1295 + Ipamorelin Blend is used in research
Areas of study described in the published literature. Listed for research reference only.
Growth hormone release
Studied for the combined effect of GHRH and ghrelin-receptor stimulation on pulsatile GH secretion.
Metabolic regulation
Used in research on the GH/IGF-1 axis and downstream metabolic and body-composition endpoints.
Receptor pharmacology
Applied to investigate signaling at the GHRH receptor and the ghrelin/GHS-R1a receptor in parallel.
Secretagogue selectivity
Explored in study designs comparing selective GH release against off-target pituitary hormone effects.
Mechanism in research
How CJC-1295 + Ipamorelin Blend is studied
In published research the two compounds engage distinct receptors that converge on growth hormone release from pituitary somatotrophs. CJC-1295, a GHRH analogue, has been reported to produce sustained increases in growth hormone and IGF-I in healthy adults, while Ipamorelin was characterized as the first selective growth hormone secretagogue, stimulating GH release without significantly affecting ACTH or cortisol. The blend is studied for how these GHRH and ghrelin-receptor pathways may interact; combined mechanisms and outcomes in humans are not established.
Reported targets & pathways
- GHRH receptor
- Ghrelin / GHS-R1a receptor
- Pituitary somatotroph GH release
- IGF-1 axis
Selected research
Published studies on CJC-1295 + Ipamorelin Blend
Peer-reviewed references for further reading. Findings describe in-vitro and animal research; mechanisms and outcomes in humans are not established.
Journal of Clinical Endocrinology & Metabolism · 2006
Reported that subcutaneous CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-I in healthy adults.
European Journal of Endocrinology · 1998
Characterized Ipamorelin as the first selective growth hormone secretagogue, reporting GH release comparable to GHRH without significant ACTH or cortisol elevation.
Comparison
CJC-1295 + Ipamorelin vs the standalone compounds
| Blend | CJC-1295 (No DAC) | Ipamorelin | |
|---|---|---|---|
| Receptor target | GHRH + ghrelin (GHS-R1a) | GHRH receptor | Ghrelin / GHS-R1a |
| Class | GHRH analogue + GHRP | GHRH(1-29) analogue | Selective GH secretagogue |
| Per-vial amount | 5mg + 5mg (10mg) | 5mg / 10mg | 10mg |
| Research focus | Combined GH pathway | Pulsatile GH release | Selective GH release |
Quality
Independently verified, batch by batch
Tested every batch
Every batch of CJC-1295 + Ipamorelin Blend is independently analyzed by a third-party laboratory before it is released.
Independently verified
Identity and purity are confirmed by an independent third-party laboratory. This batch is verified to 99.4% purity.
Certificate of analysis
Every batch is independently tested with a certificate of analysis. A digital COA is available on request.
Reviews
What researchers say about CJC-1295 + Ipamorelin Blend
quick to reply
emailed a couple questions about the blend before ordering and someone got back the same day, which is more than i can say for the last place. reached singapore fine, vials all intact
our default now
works out cheaper than buying cjc and ipamorelin separate and does the same job for us, so we keep reordering. columbus this time, no drama
sealed and tidy
grabbed more of the blend for the lab and had it sent to glasgow, came sealed with the lot printed clear on every vial and packed tight enough that nothing shifted in transit
fits our screening routine
we run the combined vial for routine gh secretagogue screening here in yokohama. went with it mainly to save a prep step when were doing plates back to back, and it reconstitutes clear with no haze. response in our assay sat about where we expected. its staying in the rotation
support actually replied
third blend order now, this one to montreal. had a question about the lot before i ordered and they got back within the hour, which honestly surprised me. blends been steady for our gh work
wie immer
Kam problemlos in die Schweiz, gut verpackt und die Charge sieht aus wie die letzte
CJC-1295 + Ipamorelin Blend FAQ
Related Products
KLOW Blend
99.41% pureQuad-peptide research blend of TB-500, BPC-157, GHK-Cu, and KPV, co-lyophilized in a single 80mg vial for combined tissue-repair and anti-inflammatory pathway studies.
GLOW Blend
99.36% pureTriple-peptide research blend of TB-500, BPC-157, and GHK-Cu, co-lyophilized in a single 70mg vial for combined tissue-repair and remodeling pathway studies.
BPC-157 + TB-500 Blend
99.28% pureDual-peptide research blend of BPC-157 and TB-500 in a 50/50 split, co-lyophilized for focused tissue-repair and regeneration pathway studies. Available in 10mg and 20mg vials.
